AbbVie Inc. (ABBV) News and Biopharmaceutical & Healthcare Updates
AbbVie Inc., headquartered in North Chicago, Illinois, develops advanced therapies in immunology, oncology, neuroscience, eye care, and medical aesthetics. Its key products include Humira, Skyrizi, and Botox (via Allergan). AbbVie focuses on research-driven innovation and expanding patient access to next-generation treatments worldwide.
286
2.9790
1.03 %
At close
11/03
USD
Daily range
284.70
291.32
291.32
Weekly range
281.64
298.50
298.50
AbbVie stock weekly forecast: MACD and ADX support further upside as momentum trends higher
Shares of AbbVie Inc. (ABBV) are trading near $289 after dipping around 2% this week, with buyers remaining in control despite the pullback. The stock continues to hold ...
AbbVie shares drop almost 2% after strong Q3 results and raised dividend
AbbVie Inc. (ABBV) fell 1.9% after posting strong third-quarter earnings and increasing its dividend, even as robust results and raised guidance provided a fundamentally constructive backdrop. The ...
AbbVie shares Q3 2026 financial results after stock ends session up 1.7%
AbbVie unveiled its Q3 2026 financial results in a company video update. The stock is up 1.7% on the day at $290.97.AbbVie shared a video highlighting its Q3 2026 financial results, displaying its ...
AbbVie stock rises 1.7% after Q3 2026 earnings call announcement
AbbVie will hold its third-quarter 2026 earnings call and webcast on October 30. The stock is up 1.7% on the day at $290.97.AbbVie will hold its third-quarter 2026 earnings call and webcast on ...
AbbVie announces Q3 2026 earnings call while stock holds steady
AbbVie will host its third-quarter earnings call on October 30 at 8am CT. The stock is little changed on the day, trading near $286.44.AbbVie announced it will hold its third-quarter 2026 earnings ...
AbbVie stock holds steady as Q3 2026 financial results investor call
AbbVie announced plans for an investor call on October 30 to discuss its third-quarter 2026 results. Shares are little changed on the day, trading near $286.44.AbbVie announced on October 15, 2026 ...
AbbVie stock weekly forecast: Remains supported above the 20-day average
Shares of AbbVie Inc. (ABBV) are trading near $286, as buyers retained control through the past week, keeping the stock near recent highs. With the uptrend intact, focus ...
AbbVie stock weekly forecast: Recent rally steadies as resistance looms at $291.36
Shares of AbbVie Inc. (ABBV) are trading near $287, holding steady after a quiet week where the recovery remained intact. As the rally shows signs of becoming stretched, ...
AbbVie stock rallies as upward price move follows strong Skyrizi trial and FDA news
AbbVie (ABBV) stock is trading at $283.64, up 3.38% on the day and showing a strong daily gain. The price sits comfortably above its key moving averages, reflecting ...
ABBV slides around 2.5% as technical indicators warn of overbought conditions despite bullish momentum
AbbVie Inc. (ABBV) fell 2.53% after opening with solid gains, as traders took profits following a string of positive corporate milestones, including a major acquisition and strong quarterly ...
AbbVie shares weekly forecast: Ongoing consolidation supported by Ichimoku Kijun level at $262.5
Shares of AbbVie Inc. (ABBV) are trading near $279 as the recovery setup persists, but momentum is increasingly stretched. The small upside this week reflects a ...
Why is AbbVie stock up 1.8% today?
AbbVie Inc. (ABBV) is climbing 1.82% after securing two FDA Breakthrough Therapy Designations for its oncology candidate telisotuzumab adizutecan, supporting strong buying interest. This move is ...
Why are AbbVie shares down 2% today?
AbbVie Inc. (ABBV) fell 2.03% following a series of positive corporate announcements, including regulatory milestones and strong earnings, even as selling pressure persisted after a downside gap. ...
Epcoritamab plus R-CHOP Phase 3 results: Can AbbVie stock break $279.47 resistance?
AbbVie Inc. (ABBV) stock is trading at $274.75, up 3.02% for the day. The price stands firmly above its key moving averages, reflecting strong near-term ...
AbbVie stock weekly forecast: Holds gains as buyers stay in control
Shares of AbbVie Inc. (ABBV) are holding near $262 as buyers remain in control, keeping the recent price action stable despite limited movement over the past week. With ...
AbbVie shares weekly forecast: recovery holds but faces a stretched setup
Shares of AbbVie Inc. (ABBV) are trading near $265 as a cautious recovery setup remains in place, with price action holding steady within a stretched short-term range. ...
AbbVie stock edges lower after European Commission approval for pJIA treatment
AbbVie said the European Commission has approved its treatment for active polyarticular juvenile idiopathic arthritis in children as young as two who have not responded to DMARDs. Shares edge ...
AbbVie shares weekly forecast: Corporate news flow supports steady climb but resistance caps upside
Shares of AbbVie Inc. (ABBV) are trading near $266 as a slow upward grind keeps the recovery intact, with conditions now looking stretched at the top of the recent ...
AbbVie announces collaboration agreement with Iambic: Can ABBV break above $266.24?
AbbVie announced a partnership with Iambic to accelerate AI-driven drug discovery in immunology, neuroscience and oncology. The stock is little changed on the day, trading near $263.78.AbbVie ...
AbbVie stock faces resistance at $254.08 with bounce potential in focus: weekly analysis
Shares of AbbVie Inc. (ABBV) are trading near $252 as a more than 1.5% decline stretched the stock into oversold territory last week. Conflicting signals from momentum ...
What's behind AbbVie's latest 2.3% stock pullback?
AbbVie Inc. (ABBV) fell 2.28% after the company reported strong second-quarter 2026 results and completed the acquisition of Apogee Therapeutics, integrating zumilokibart into its portfolio. The ...
